Clinical Trial Search

Primary: Percentage of Participants Achieving Clinical Remission (CR) at Week 52 Using Modified Mayo Score (MMS) — 26.0; 18.3 Percentage of participants — p=0.2524

Primary: Number of Participants Enrolled Across Cohorts — 41; 36 Participants

Primary: Safety, Tolerability and Effectiveness in Reducing Dental Plaque of KLS-W Delivered in a Chewing Gum Formulation — 0; 0; 0; 0 participants

Primary: Change in Core Temperature — 1.19; 1.09; 1.20; 0.89 Celsius

Primary: Neurocognitive Function — 73.68; 74.04; 3.36; 3.96 Total score

Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Week 6 — -16.0; -15.4 Units on a scale — p==0.438

Primary: Number of Participants Disease-free Until Completion of Treatment (2 Years From Start of ADT)

Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants

Primary: Delirium — 5; 6; 5; 6 Participants

Primary: Overall Response Rate — 0 percentage of participants

Primary: Progression Free Survival (PFS) — 4.17; 2.43 Months — p=0.204

Primary: 1-year Progression Free Survival (PFS) Rate for ccRCC Patients — 34.6; 53.8; 33.3; 75 Percentage of participants

Primary: Time to Worsening of DME Disease Activity in the Study Eye. — 82.1; 96.1; 19.1 Weeks

Primary: Indapamide: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM - Censored Data — -3.7; -15.7 mmHg — p=<0.0001

Primary: Relative to Baseline Alanine Aminotransferase (ALT) — 0.959; 0.895 Ratio — p=0.893